Formulation Development
World’s First Zero-Off-Target Base-Edited NK Cell Therapy Receives IND Approval in Both China & US
Base Therapeutics recently announced its NK510 cell injection, the world’s first zero-off-target base-edited NK cell product, has received IND approvals from both the US FDA…
TILT Biotherapeutics Provides Update on International Clinical Trial Progress With Intravenous Delivery Regimen for Cancer Immunotherapies
TILT Biotherapeutics (TILT) recently announced it will be presenting data at the European Society of Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2024. The oral presentation discloses…
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology, Inc. recently announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus…
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
Denali Therapeutics Inc. recently announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2)…
Samabriva Accelerates its Growth With New State-of-the-Art Biomanufacturing Facility
Samabriva recently announced the opening of a new 1,400 m² biomanufacturing facility in Liege, Belgium, at the heart of European’s biotech valley. This strategic investment…
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious US Medical Centers
Tiziana Life Sciences, Ltd. recently announced the expansion of its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS). The…
8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Namodenoson Drug
Can-Fite BioPharma Ltd. recently announced a patient currently treated with Namodenoson in a compassionate use program in Can-Fite’s Phase 2 Liver Cancer Study has an…
Amarna Therapeutics Partners With NorthX Biologics to Advance Gene Therapy Development
Amarna Therapeutics recently announced its strategic collaboration with NorthX Biologics, a leading biologics manufacturing partner. This partnership represents a major step in advancing the clinical…
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals
Medigene AG recently announced a $1 million milestone payment from Regeneron Pharmaceuticals, Inc. was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition…
Roivant Announces Topline Results From Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Kinevant Sciences recently announced its Phase 2 study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. The Phase 2 RESOLVE-Lung study…
Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 Million to Intas Pharmaceuticals Ltd.
Coherus BioSciences, Inc. recently announced it has entered into an asset purchase agreement (the Agreement) dated December 2, 2024, with Intas Pharmaceuticals Ltd. (Intas) for…
Palisade Bio Announces Preliminary Data From Phase 1 Clinical Study for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe & Well Tolerated
Palisade Bio, Inc recently announced preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human clinical study for…
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 Clinical Trial
Kairos Pharma Ltd. recently announced the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for…
Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of a Potential First-in-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors & Lymphoma
Recursion recently announced the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of…
Lonza Launches Tailored Offering for Smart Capsules Companies Developing Oral Delivery Solutions for Biologic Drugs
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, recently announced an expansion of its service offering for orally delivered biologic therapies…
Veranova Recognized as One of SOCMA’s 25 Companies for Industry-Leading Safety Programs
Veranova recently announced it has been recognized by The Society of Chemical Manufacturers & Affiliates, Inc. (SOCMA) as a recipient of its prestigious 2024 Safety…
Olema Oncology Announces New Clinical Trial Collaboration & Supply Agreement
Olema Pharmaceuticals, Inc. recently announced a new clinical trial collaboration and supply agreement with Novartis in frontline metastatic breast cancer. Olema has also entered into…
PTC Therapeutics Enters Global License & Collaboration Agreement With Novartis
PTC Therapeutics, Inc. recently announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:…
Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1
Ocular Therapeutix, Inc. recently announced more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI (axitinib intravitreal implant, also known…
NovelMed Receives FDA IND Approval for the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder
NovelMed recently announced the US FDA has granted clearance for Ruxoprubart, an investigational drug, to commence an efficacy trial for the treatment of Immunoglobulin A…
